<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368783</url>
  </required_header>
  <id_info>
    <org_study_id>2011-ATV</org_study_id>
    <nct_id>NCT01368783</nct_id>
  </id_info>
  <brief_title>Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers</brief_title>
  <official_title>Two Randomized, Open-labeled, Parallel Designed Multiple-dose Clinical Trials to Evaluate Pharmacokinetics of Ritonavir-unboosted and Ritonavir-boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      Compared to those of Caucasians, the plasma levels of atazanavir (ATV) may be higher in
      Koreans with the same dosage regimen(s). If so, even unboosted ATV could be used with
      tenofovir DF (TDF) which lowers the concentration of ATV. The investigators plan to
      investigate the pharmacokinetic features of ATV with or without TDF in healthy Korean and
      Caucasian volunteers and compare the ethnic differences.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic analysis</measure>
    <description>maximum concentration at steady status(Cmax,ss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <description>Area under the time-concentration curve, at steady status, at tau(τ) (AUCτ,ss)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Atazanavir</condition>
  <arm_group>
    <arm_group_label>atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg/day for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir and Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir and Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir + tenofovir + ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>400 mg/day for 2 days</description>
    <arm_group_label>atazanavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir(ATZ) and Tenofovir(TDF)</intervention_name>
    <description>ATZ 400 mg with TDF/day for 2 days</description>
    <arm_group_label>Atazanavir and Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir(ATZ) + Ritonavir</intervention_name>
    <description>ATZ 300 mg + Ritonavir 100 mg/day for 2 days</description>
    <arm_group_label>Atazanavir and Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir(ATZ) + tenofovir(TDF) + ritonavir</intervention_name>
    <description>ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days</description>
    <arm_group_label>Atazanavir + tenofovir + ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 20 to 55 years old, with a weight more than 50 kg and with appropriate body
             mass index (BMI) values within 19-28 kg/m2.

          -  Agreed voluntarily to participate to the study and comply with the study protocol with
             written permission.

        Exclusion Criteria:

          -  Has history of liver, kidney, respiratory, musculoskeletal, endocrinologic,
             neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).

          -  Has history of hypersensitivity or clinically significant adverse drug reaction(s) to
             the study drugs, same class of the study drugs, or other drugs including aspirin and
             antibiotics.

          -  Drinks excessive caffeinated beverages (caffeine &gt;10 units/day), alcohol beverages
             (alcohol &gt;21 units/week) or smokes excessively (&gt;20 cigarettes/day) or has history of
             alcoholism.

          -  Has been excluded by the researchers due to abnormal findings in screening EKG and/or
             blood tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyun-Seop Bae, M.D., Ph. D.</last_name>
    <phone>82-2-3010-4622</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, M.D., Ph. D.</last_name>
      <phone>82-2-3010-4622</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

